Supreme Court backs generic drugmaker in 'skinny labeling' case
Key Points:
- The Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe patents held by Amarin in a decision that makes generic drugmakers less vulnerable to lawsuits over so-called skinny lab